GNMSF vs BIIB: Which Stock is Better?
Side-by-side comparison of Genmab A/S and Biogen Inc in 2026
GNMSF
Genmab A/S
$330.37
BIIB
Biogen Inc
$165.38
Key Metrics Comparison
| Metric | GNMSF | BIIB | Winner |
|---|---|---|---|
| Market Cap | $20.35B | $24.26B | BIIB |
| P/E Ratio | 14.47 | 15.09 | GNMSF |
| EPS (TTM) | $22.83 | $10.96 | GNMSF |
| Revenue Growth | 0.2% | 0.0% | GNMSF |
| Gross Margin | 94.4% | 76.6% | GNMSF |
Analyze GNMSF
Full quant analysis
Analyze BIIB
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is GNMSF or BIIB a better investment?
Comparing GNMSF and BIIB: Genmab A/S has a market cap of $20.35B while Biogen Inc has $24.26B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between GNMSF and BIIB?
GNMSF (Genmab A/S) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: GNMSF or BIIB?
Based on P/E ratios, GNMSF trades at a lower multiple (14.5x vs 15.1x).
Which is growing faster: GNMSF or BIIB?
GNMSF has higher revenue growth at 0.2% vs 0.0% for BIIB.
Which company is more profitable: GNMSF or BIIB?
Genmab A/S (GNMSF) has higher gross margins at 94.4% compared to 76.6% for BIIB.
Which is the larger company: GNMSF or BIIB?
Biogen Inc (BIIB) is larger with a market cap of $24.26B compared to $20.35B for GNMSF.
Should I buy GNMSF or BIIB in 2026?
Both GNMSF and BIIB have investment merit. GNMSF trades at $330.37 while BIIB trades at $165.38. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between GNMSF and BIIB stock?
Key differences: Market Cap ($20.35B vs $24.26B), P/E Ratio (14.5x vs 15.1x), Revenue Growth (0.2% vs 0.0%), Gross Margin (94.4% vs 76.6%).